HOUSTON - Scientists at The University of Texas M. D. Anderson Cancer Center have discovered a gene that protects PTEN, a major tumor-suppressor that is reduced but rarely mutated in about half of all breast cancers.
The gene Rak helps protect and regulate PTEN, which also is important in several other types of cancer, the team reports in the April edition of Cancer Cell. Causes for diminished PTEN protein levels in breast cancer absent a mutation of the PTEN gene have eluded researchers, who knew for several years that a piece of the puzzle was missing.
"We've clearly discovered the missing link that explains how Rak can stabilize PTEN protein to prevent breast cancer development," said lead author Shiaw-Yih Lin, Ph.D., an assistant professor in the Department of Systems Biology at M. D. Anderson. "Our research explains why PTEN is defective in breast cancer and provides important clues for the development of effective therapy in Rak- or PTEN-defective breast cancers."
In addition to breast cancer, PTEN frequently is mutated or inactivated in glioblastoma, melanoma, and cancers of the prostate and endometrium. The severity of PTEN irregularities strongly correlates with the tumor stage and grade. For example, complete loss of PTEN expression is found more frequently in metastatic cancer than in primary tumors.
In the laboratory, researchers found Rak can stabilize PTEN protein and function as a tumor suppressor gene to prevent breast cancer development.
To examine the correlation between Rak and PTEN protein expression, researchers analyzed cells from 42 breast cancers. Rak expression showed a strong positive correlation with PTEN.
They also investigated the effect of Rak expression by injecting mice with cells that over-expressed Rak. All the mice injected with Rak-overexpressing cells remained tumor free, whereas all the control mice developed tumors.
"To further assess whether Rak is
|Contact: Scott Merville|
University of Texas M. D. Anderson Cancer Center